GuidelineJournal of clinical pathology2004
Best Practice No 176: Updated recommendations for HER2 testing in the UK.
Guideline in Journal of clinical pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.
- Updated UK Recommendations for HER2 assessment in breast cancer.Journal of clinical pathology · 2015Guideline
- Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.Health technology assessment (Winchester, England) · 2020Trial
- Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Breast cancer research : BCR · 2013Trial
- Trial
- Expression Patterns of ER, PR, HER-2/neu and p53 in Association with Nottingham Tumour Grade in Breast Cancer Patients.Sultan Qaboos University medical journal · 2023Article
- Refining the definition of HER2-low class in invasive breast cancer.Histopathology · 2022Article
- PLOD3 regulates the expression of YAP1 to affect the progression of non-small cell lung cancer via the PKCδ/CDK1/LIMD1 signaling pathway.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Updates on breast biomarkers.Virchows Archiv : an international journal of pathology · 2022Review
- KLF5 activates lncRNA DANCR and inhibits cancer cell autophagy accelerating gastric cancer progression.NPJ genomic medicine · 2021Article
- Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.British journal of cancer · 2021Observational
- Article
- Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.PharmacoEconomics · 2019Review
- KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.BMC cancer · 2018Article
- Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka.BMC women's health · 2018Article
- Prognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers.Breast cancer : basic and clinical research · 2017Article
- HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.Oncotarget · 2016Article
- Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.Pathology oncology research : POR · 2016Article
- Article
- Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.Angewandte Chemie (International ed. in English) · 2015Article
- Guidance for laboratories performing molecular pathology for cancer patients.Journal of clinical pathology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.